The aim of this study was to evaluate the effect of Momordica charantia (MC) administration on anthropometric measures in patients with obesity. A randomized, double-blind, placebo-controlled pilot clinical trial was carried out in 24 patients with obesity. Twelve patients randomly received MC (2000 mg/day) for 12 weeks, and 12 patients received placebo. Body weight (BW), body mass index (BMI), waist circumference (WC), body fat percentage, as well as clinical and laboratory determinations, were evaluated before and after the intervention. Results showed that while reductions in BW, BMI, WC, and body fat percentage were observed in the MC group, these differences did not reach statistical significance. Significant decreases in triglycerides (TG) (1.9 ± 0.6 mM vs. 1.7 ± 0.7 mM, P ≤ .05) and very low-density lipoprotein (VLDL) (0.4 ± 0.1 mM vs. 0.3 ± 0.1 mM, P ≤ .05) levels were found after the intervention with MC. In contrast, significant increases in BW (83.0 ± 10.7 kg vs. 84.6 ± 9.1 kg, P ≤ .05) and BMI (31.9 ± 1.5 kg/m2 vs. 33.0 ± 1.3 kg/m2, P ≤ .05) were observed in the placebo group. In conclusion, no significant reductions in BW, BMI, WC, and body fat percentage were observed after MC administration; however, MC significantly decreased TG and VLDL levels. The protocol was registered at ClinicalTrials.gov with the identifier NCT04916379.
Get full access to this article
View all access options for this article.
References
1.
BlüherM: Obesity: Global epidemiology and pathogenesis. Nat Rev Endocrinol, 2019; 15:288–298.
2.
WaddenTA, TronieriJS, ButrynML: Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol, 2020; 75:235–251.
3.
SurS, RayRB: Bitter melon (Momordica charantia), a nutraceutical approach for cancer prevention and therapy. Cancers, 2020; 12:2064.
4.
TanSP, KhaTC, ParksSE, RoachPD: Bitter melon (Momordica charantia L.) bioactive composition and health benefits: A review. Food Rev Int, 2016; 32:181–202.
5.
NgT, HonW, LoL, LiW, YeungH: Effects of a-momorcharin, b-momorcharin and a-trichosanthin on lipogenesis and testicular and adrenal steroidogenesis in vitro and plasma-glucose levels in vivo. J Ethnopharmacol, 1986; 18:45–53.
6.
NgT, WongC, LiW, YeungH: Acid-ethanol extractable compounds from fruits and seeds of the Bitter Gourd Momordica charantia: Effects on lipid metabolism in isolated rat adipocytes. Am J Chin Med, 1987; 15:31–42.
YamaOE, OsinubiAA, NoronhaCC, OkanlawonAO: Effect of methanolic seed extract of Momordica charantia on body weight and serum cholesterol level of male Sprague-Dawley rats. Nig Q J Hosp Med, 2010; 20:209–213.
9.
PinaF, BrownA, LuebckeE, et al.: Momordica charantia improves body weight and glucose tolerance in mice fed high fat diet. FASEB J 2009;23:563.37.
10.
ChenQ, ChanLLY, LiETS: Bitter Melon (Momordica charantia) reduces adiposity, lowers serum insulin and normalizes glucose tolerance in rats fed a high fat diet. J Nutr, 2003; 133:1088–1093.
11.
BanoF, AktharN, NazH: Effect of the aqueous extract of Momordica charantia on body weight of rats. J Basic Appl Sci, 2011; 1:1–5.
12.
ShihC-C, LinC-H, LinW-L: Effects of Momordica charantia on insulin resistance and visceral obesity in mice on high-fat diet. Diabetes Res Clin Pract, 2008; 81:134–143.
13.
Cortez-NavarreteM, Martínez-AbundisE, Pérez-RubioKG, González-OrtizM, Méndez del VillarM: Momordica charantia administration improves insulin secretion in Type 2 Diabetes mellitus. J Med Food, 2018; 21:672–677.
14.
Soo MayL, SanipZ, Ahmed ShokriA, Abdul KadirA, Md LazinMR: The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial. Complement Ther Clin Pract, 2018; 32:181–186.
JeyaseelanL, RaoPS: Methods of determining sample sizes in clinical trials. Indian Pediatr, 1989; 26:115–121.
17.
JungK, KimJ, ParkHY, JungWS, LimK: Hypoxic Pilates Intervention for Obesity: A Randomized Controlled Trial. Int J Environ Res Public Health, 2020; 17:7186.
18.
VenniyoorA: Obesity-related cancers: The coming epidemic. Indian J Med Paediatr Oncol, 2020; 41:328–334.
19.
Ríos-HoyoA, Gutiérrez-SalmeánG: New dietary supplements for obesity: What we currently know. Curr Obes Rep, 2016; 5:262–270.
20.
ShobhaCR, PrashantV, AkilaP, ChandiniR, SumaMN, BasavanagowdappaH: Fifty percent ethanolic extract of Momordica charantia inhibits adipogenesis and promotes adipolysis in 3T3–L1 pre-adipocyte cells. Rep Biochem Mol Boil, 2017; 6:22–32.
21.
HuangHL, HongYW, WongYH, et al.: Bitter melon (Momordica charantia) inhibits adipocyte hypertrophy and down regulates lipogenic gene expression in adipose tissue of diet-induced obese rats. Br J Nutr, 2008; 97:230–239.
22.
ChanLLY, ChenQ, GoAGG, LamEKY, LiETS: Reduced adiposity in Bitter Melon (Momordica charantia)–Fed rats is associated with increased lipid oxidative enzyme activities and uncoupling protein expression. J Nutr, 2005; 135:2517–2523.
KrawinkelMB, LudwigC, SwaiME, YangR, ChunKP, HabichtSD: Bitter gourd reduces elevated fasting plasma glucose levels in an intervention study among prediabetics in Tanzania. J Ethnopharmacol, 2018; 216:1–7.
26.
KinoshitaH, OgataY: Effect of Bitter Melon extracts on lipid levels in Japanese subjects: A randomized controlled study. Evid Based Complement Altern Med, 2018; 2018:1–6.
27.
RahmanIU, KhanRU, RahmanKU, BashirM: Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr J, 2015; 14:13–19.
28.
DansAML, VillarruzMVC, JimenoCA, et al.: The effect of Momordica charantia capsule preparation on glycemic control in Type 2 Diabetes mellitus needs further studies. J Clin Epidemiol, 2007; 60:554–559.
29.
BhutaniS, VanDellenMR, CooperJA: Longitudinal Weight Gain and Related Risk Behaviors during the COVID-19 Pandemic in Adults in the US. Nutrients, 2021; 13:671.
30.
BhutaniS, CooperJA, VanDellenMR: Self-reported Changes in Energy Balance Behaviors during COVID-19-related Home Confinement: A Cross-sectional Study. Am J Health Behav, 2021; 45:756–770.
31.
WangJ, RyuHK: The effects of Momordica charantia on obesity and lipid profiles of mice fed a high-fat diet. Nutr Res Pract, 2015; 9:489–495.
32.
FernandesNP, LagishettyCV, PandaVS, NaikSR: An experimental evaluation of the antidiabetic and antilipidemic properties of a standardized Momordica charantia fruit extract. BMC Complement Altern Med, 2007; 7:29.
33.
AhmedI, LakhaniMS, GillettM, JohnA, RazaH: Hypotriglyceridemic and hypocholesterolemic effects of anti-diabetic Momordica charantia (karela) fruit extract in streptozotocin-induced diabetic rats. Diabetes Res Clin Pract, 2001; 51:155–161.
34.
ChaturvediP, GeorgeS: Momordica charantia maintains normal glucose levels and lipid profiles and prevents oxidative stress in diabetic rats subjected to chronic sucrose load. J Med Food, 2010; 13:520–527.
MacekP, Terek-DerszniakM, BiskupM, et al.: A Two-year follow-up cohort study-improved clinical control over CVD risk factors through weight loss in middle-aged and older adults. J Clin Med, 2020; 9:2904.
37.
BrowningJD, BakerJA, RogersT, DavisJ, SatapatiS, BurgessSC: Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr, 2011; 93:1048–1052.
38.
ChanDC, WattsGF, NgTW, YamashitaS, BarrettPH: Effect of weight loss on markers of triglyceride-rich lipoprotein metabolism in the metabolic syndrome. Eur J Clin Invest, 2008; 38:743–751.
39.
ValsamakisG, McTernanPG, ChettyR, et al.:Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004;53:430–434.
40.
BlackburnG: Effect of degree of weight loss on health benefits. Obes Res, 1995; 3:211–216.
